For investors hunting for opportunities in the healthcare sector, REGENXBIO Inc. (NASDAQ: RGNX) presents a compelling case with its strong potential upside. The biotechnology company, headquartered in Rockville, Maryland, focuses on developing gene therapies aimed at addressing genetic defects. Leveraging its proprietary NAV Technology Platform, REGENXBIO is making strides in treating a range of conditions from wet age-related macular degeneration to Duchenne muscular dystrophy.

Currently valued at approximately $425.74 million, REGENXBIO’s stock is trading at $8.41. The company has experienced a price change of 0.51, representing a modest 0.06% increase. Over the past year, its stock price has fluctuated between $5.31 and…